Literature DB >> 11641252

Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action.

M La1, M D'Amico, S Bandiera, C Di Filippo, S M Oliani, F N Gavins, R J Flower, M Perretti.   

Abstract

Myocardial reperfusion injury is associated with the infiltration of blood-borne polymorphonuclear leukocytes. We have previous described the protection afforded by annexin 1 (ANXA1) in an experimental model of rat myocardial ischemia-reperfusion (IR) injury. We examined the 1) amino acid region of ANXA1 that retained the protective effect in a model of rat heart IR; 2) changes in endogenous ANXA1 in relation to the IR induced damage and after pharmacological modulation; and 3) potential involvement of the formyl peptide receptor (FPR) in the protective action displayed by ANXA1 peptides. Administration of peptide Ac2-26 at 0, 30, and 60 min postreperfusion produced a significant protection against IR injury, and this was associated with reduced myeloperoxidase activity and IL-1beta levels in the infarcted heart. Western blotting and electron microscopy analyses showed that IR heart had increased ANXA1 expression in the injured tissue, associated mainly with the infiltrated leukocytes. Finally, an antagonist to the FPR receptor selectively inhibited the protective action of peptide ANXA1 and its derived peptides against IR injury. Altogether, these data provide further insight into the protective effect of ANXA1 and its mimetics and a rationale for a clinical use for drugs developed from this line of research.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11641252     DOI: 10.1096/fj.01-0196com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  51 in total

1.  Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies.

Authors:  Aleksey Nakorchevsky; Johannes A Hewel; Sunil M Kurian; Tony S Mondala; Daniel Campbell; Steve R Head; Christopher L Marsh; John R Yates; Daniel R Salomon
Journal:  J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 10.121

Review 2.  Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.

Authors:  Mauro Perretti; Jesmond Dalli
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

3.  miR-146a and miR-196a2 polymorphisms in patients with ischemic stroke in the northern Chinese Han population.

Authors:  Ruixia Zhu; Xu Liu; Zhiyi He; Qu Li
Journal:  Neurochem Res       Date:  2014-06-22       Impact factor: 3.996

4.  Annexin A1 regulates intestinal mucosal injury, inflammation, and repair.

Authors:  Brian A Babbin; Mike G Laukoetter; Porfirio Nava; Stefan Koch; Winston Y Lee; Christopher T Capaldo; Eric Peatman; Eric A Severson; Roderick J Flower; Mauro Perretti; Charles A Parkos; Asma Nusrat
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.

Authors:  Josh C Woloszynek; Ying Hu; Christine T N Pham
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

6.  Recombinant annexin A6 promotes membrane repair and protects against muscle injury.

Authors:  Alexis R Demonbreun; Katherine S Fallon; Claire C Oosterbaan; Elena Bogdanovic; James L Warner; Jordan J Sell; Patrick G Page; Mattia Quattrocelli; David Y Barefield; Elizabeth M McNally
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

7.  Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles.

Authors:  Nazila Kamaly; Gabrielle Fredman; Manikandan Subramanian; Suresh Gadde; Aleksandar Pesic; Louis Cheung; Zahi Adel Fayad; Robert Langer; Ira Tabas; Omid Cameron Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

8.  Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair.

Authors:  Giovanna Leoni; Ashfaqul Alam; Philipp-Alexander Neumann; J David Lambeth; Guangjie Cheng; James McCoy; Roland S Hilgarth; Kousik Kundu; Niren Murthy; Dennis Kusters; Chris Reutelingsperger; Mauro Perretti; Charles A Parkos; Andrew S Neish; Asma Nusrat
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

9.  Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells.

Authors:  Florence Borot; Diane-Lore Vieu; Grazyna Faure; Janine Fritsch; Julien Colas; Sandra Moriceau; Maryvonne Baudouin-Legros; Franck Brouillard; Jesus Ayala-Sanmartin; Lhousseine Touqui; Marc Chanson; Aleksander Edelman; Mario Ollero
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

10.  Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils.

Authors:  Heike L Rittner; Dagmar Hackel; Philipp Voigt; Shaaban Mousa; Andrea Stolz; Dominika Labuz; Michael Schäfer; Michael Schaefer; Christoph Stein; Alexander Brack
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.